| Symbol | AVLN |
|---|---|
| Name | AVALYN PHARMA INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 105 W FIRST ST., BOSTON, MA 02127 |
| Telephone | (206) 707-0340 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001540171 |
| Description | None |
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Read moreAvalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026
Read moreNew Form SCHEDULE 13G - Avalyn Pharma Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001388325-26-000044 <b>Size:</b> 6 KB
Read more(10% Negative) AVALYN PHARMA INC. (AVLN) Reports Q3 2026 Financial Results
Read moreAvalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Read moreNew Form SCHEDULE 13G - Avalyn Pharma Inc. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0002149521-26-000002 <b>Size:</b> 18 KB
Read more(30% Negative) AVALYN PHARMA INC. (AVLN) Announces Delay in investigator Trials for lung function Due to Patient Enrollment Issues, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreAvalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Read more(10% Negative) AVALYN PHARMA INC. (AVLN) Announces Delay in programs Trials for Avalyn Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment
Read moreAvalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Read more